One of the rare diseases, “pulmonary arterial hypertension”, paved the way for a more active treatment.
Pulmonary arterial hypertension is a disease in which blood pressure rises in the pulmonary artery that supplies blood from the heart to the lungs. The prevalence rate is between 15 and 60 per 1 million people.
Pulmonary arterial hypertension is not easy to diagnose because its symptoms are nonspecific. Professor Park Jae-hyung, from the Department of Cardiology at National Chungnam University, said: “Symptoms like chronic fatigue, swelling, shortness of breath and dizziness appear.”
Currently, about 1,500 patients are being treated for pulmonary arterial hypertension in Korea, but it is estimated that there are 4,000 to 6,000 hidden patients who are not actually diagnosed and treated due to the difficulty of early diagnosis.
The process after starting treatment is also not smooth. Compared to advanced countries like Japan and the United States, the survival rate is very low. Professor Park Jae-hyung said: “The three-year survival rate in Japan is 96%, while in Korea it is only 55%. Five-year survival is also 74% in Japan and 46% in Korea, ”he explained.
There is a desperate need for standard treatment guidelines that adapt to the domestic situation. Thus, a special committee that recently established guidelines for pulmonary hypertension has prepared guidelines for treatment.
Professor Jang Hyeok-jae of cardiology at Yonsei University said: “Although it is a disease that can exceed 90% of the survival rate if treated well, Korea is getting significantly lower scores than that. The creation of the instructions is complete. Soon, 12 groups of experts will be concluded. “
The goal of treating pulmonary arterial hypertension is to reduce the high or medium risk to the low risk. To do this, a combination treatment of active drugs is required. Although insurance standards are currently strict and a number of excellent treatment drugs have been introduced in Korea, the reduction due to combined treatment has forced the use of medicines conservatively.
Therefore, this guideline reflects in the insurance system the recommendation that therapy with two drugs should be considered from the initial treatment, and that additional combination therapy should be performed if the patient does not reach a low risk state after 3 to 6 months. treatment with the second drug.
It is necessary to improve the situation in which patients who can live their daily lives if they receive a good treatment remain in a state that can barely avoid hospitalization. The purpose of publishing this guideline is to raise the current level of ambiguous management of the patient to the level of advanced countries, so that patients who are unable to climb the first and second floors of breathless stairs can lead a more normal life.
Reporter Moon Se-young [email protected]
Copyrightⓒ’Honest Knowledge for Health ‘Comedy.com (http://kormedi.com) / Unauthorized reproduction-redistribution prohibited